Iron chelation and Vibrio vulnificus

Iron chelation and Vibrio vulnificus

Vibrio
Researchers from Chosun University, Research Center detail findings in
vibrio

February 1st, 2007


(NewsRx . com ) -- Data detailed in "Ferrophilic characteristics of Vibrio
vulnificus and potential usefulness of iron chelation therapy" have
been presented. According to recent research from Korea, "We determined
the ferrophilic characteristics of Vibrio vulnificus to evaluate the
potential usefulness of iron chelation therapy for the prevention of V.
vulnificus infection. Readily available non-transferrin-bound iron
(NTBI) is required for the initiation of V. vulnificus growth under in
vitro iron-limited conditions and human ex vivo conditions."
"NTBI aided efficient transferrin-bound iron (TBI) use by V.
vulnificus, and the vulnibactin-mediated iron-uptake system was
expressed after bacterial growth had been started by NTBI. V.
vulnificus required higher NTBI levels for the initiation of growth,
produced siderophores at lower levels, and used TBI less efficiently
than other bacteria. In addition, the growth of V. vulnificus was
inhibited by deferiprone, a clinically available iron chelator," wrote
C.M. Kim and colleagues, Chosun University, Research Center.

The researchers concluded: "These results show that V. vulnificus is
a ferrophilic bacterium that requires higher NTBI levels than other
pathogens and that iron chelation therapy might be an effective means
of preventing the in vivo growth of V. vulnificus in susceptible
patients."

Kim and colleagues published their study in the Journal of
Infectious Diseases (Ferrophilic characteristics of Vibrio vulnificus
and potential usefulness of iron chelation therapy. Journal of
Infectious Diseases, 2007;195(1):90-8).

For additional information, contact C.M. Kim, Research Center for
Resistant Cells, Chosun University Medical School, Gwangju 501-759,
Republic of Korea.

Publisher contact information for the Journal of Infectious Diseases
is: University Chicago Press, 1427 E 60th St., Chicago, IL 60637-2954,
USA.

Keywords: Korea, Ferro Corporation Pharmaceutical Technologies,
Pharmaceutical Business, Pharmaceutical Company, Vibrio.

This article was prepared by NewsRx editors from staff and other
reports. Copyright 2007, NewsRx . com .

Who loves ya.
Tom


Jesus Was A Vegetarian!
* jesuswasavegetarian.7h . com


Man Is A Herbivore!
* tinyurl . com /a3cc3


DEAD PEOPLE WALKING
* tinyurl . com /zk9fk